Intellia Therapeutics Inc (NASDAQ: NTLA), a Cambridge, Massachusetts, company, fell to close at $163.25 Tuesday after losing $13.53 (7.65%) on volume of 1,287,465 shares. The stock ranged from a high of $180.59 to a low of $163.04 while Intellia’s market cap now stands at $11,996,760,260.
About Intellia Therapeutics Inc
Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.
Visit Intellia Therapeutics Inc’s profile for more information.
About The Nasdaq Stock Market
The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world’s leading exchange for options volume and is home to the five largest US companies – Apple, Microsoft, Amazon, Alphabet and Facebook.
To get more information on Intellia Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Intellia Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: www.equities.com/disclaimer
Read more here: Source link